In the Press

Can DalCor Pharma Succeed Where Others Have Failed?

After the worldwide success of statins, no one expected the epic failure of a class of drugs designed by the biggest names in Big Pharma to double the reduction in cardiac risk seen with statins alone. Statins lowered LDL, the bad cholesterol. The new drugs,...

Genetically Targeting Dalcetrapib to the Right Patients

DalCor Pharmaceuticals seeks to deliver superior clinical cardiovascular outcomes by integrating clinical and genetic insights to target treatments to patients who will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients. We...

Dalcor CVOT moves along; seek dalcetrapib CETP win with Roche diagnostic test

With enrollment about six months ahead of schedule, precision medicine specialist Dalcor Pharmaceuticals Inc. has randomized more than 1,000 patients of the expected 5,000 for the phase III dal-Gene trial, a cardiovascular outcomes (CVOT) study of dalcetrapib in patients with acute coronary syndrome (ACS) who...

Startup Aims To Revive Failed Drug

A London-based startup is making a risky bet that a surprising genetic variation will enable it to find success in one of the pharmaceutical industry’s biggest flops.  DalCor Pharmaceuticals said it has raised $150 million in venture financing to mount a 5,000-patient trial of a...

With $150M in the bank, Dalcor seeks phase III success with dalcetrapib

Seeking to succeed where big pharma failed, start-up Dalcor Pharma UK Ltd. completed a $100 million series B round to put an exclamation point on the $50 million series A the company closed late in 2015. The company was launched a year ago by Sanderling...